Vivos Therapeutics, Inc. - VVOS STOCK NEWS

Vivos Therapeutics (NASDAQ: VVOS) announced a review of its revenue recognition policies, concluding that minimal adjustments are needed for prior financial results. The first quarter 2022 revenue is set to increase by about $200,000, with no revenue lost. The company will restate its financials without needing to amend previous audited annual statements. Vivos will file restated Q1 2022 results and anticipates submitting Q2 and Q3 2022 reports by year-end. The adjustments will not impact cash flows or liquidity, ensuring Nasdaq compliance for financial filings.

Vivos Therapeutics (NASDAQ: VVOS) announced it received a compliance notice from Nasdaq for failing to timely file its Form 10-Q for the quarter ended June 30, 2022. This is due to ongoing reviews of financial statements and discussions over revenue recognition policies. The company has 60 days from August 23, 2022, to file the report to regain compliance. If they fail to do so, Nasdaq may initiate suspension and delisting procedures. The company is working to complete the filing as soon as possible.

Vivos Therapeutics (NASDAQ: VVOS) announced a delay in its Q2 2022 financial results, citing a need for a reevaluation of its revenue recognition policy under ASC Topic 606. CEO Kirk Huntsman assured investors that the delay is not indicative of the company's overall health. Despite the delay, Vivos reported strong sales in June with record appliance sales and new provider enrollments. The company is implementing cost-cutting measures and anticipates potential positive cash flow by early 2024.

Vivos Therapeutics (NASDAQ: VVOS) announced the rescheduling of its second quarter financial results originally set for August 15, 2022, due to discussions with its accountants over revenue recognition policies under ASC Topic 606. The new date for the financial results release and conference call is expected on or before August 22, 2022. Vivos specializes in treating dentofacial abnormalities and obstructive sleep apnea through innovative, non-invasive methods.

Vivos Therapeutics (NASDAQ: VVOS) is set to announce its Q2 2022 financial results after market close on August 15, 2022. A conference call will follow at 5:00 PM ET that day to discuss the results and company milestones. Vivos specializes in treatments for dentofacial abnormalities and conditions like obstructive sleep apnea (OSA), with its Vivos Method providing a non-invasive solution to approximately 28,000 patients treated globally. The call can be accessed via dial-in or online webcast, with a replay available until August 29, 2022.

Vivos Therapeutics has received multiple Class I clearances from the Therapeutic Goods Administration in Australia for its oral appliances, enabling treatment for obstructive sleep apnea (OSA) in patients of all ages and severities. This regulatory win validates the technology's clinical safety and efficacy. Vivos aims to expand its international market presence, having previously secured clearances in the U.S. and Canada. These advancements indicate a significant step forward for addressing the global issue of poor sleep health.

Vivos Therapeutics (NASDAQ: VVOS) has secured an exclusive distribution agreement with GM Instruments, becoming the sole U.S. and Canadian distributor of the NR6 Rhinomanometer, an FDA-approved device for assessing nasal breathing in patients with sleep and breathing issues. This collaboration is expected to enhance Vivos' revenue stream and competitive positioning by providing dentists with critical tools for evaluating and treating conditions like obstructive sleep apnea (OSA). The agreement marks a significant step in Vivos' commitment to improving patient outcomes through innovative diagnostics.

Vivos Therapeutics (NASDAQ: VVOS) presented a retrospective study at the SLEEP 2022 Annual Meeting, highlighting positive results from 786 patients using its proprietary oral appliances. The study found a 4.5% increase in transpalatal widths and an 11.1% increase in airway volume. Notably, 61.6% of the subset of patients showed a reduction of over 50% in the Apnea Hypopnea Index (AHI). Vivos' Complete Airway Repositioning and/or Expansion (CARE) therapy may represent a significant advancement for OSA treatment, offering a finite treatment duration of 12-24 months.

Vivos Therapeutics, Inc. (NASDAQ: VVOS) announced two presentations at SLEEP 2022, an event hosted by the Associated Professional Sleep Societies in Charlotte, N.C., from June 4 to 8, 2022. Dr. Seth Heckman will present a retrospective study on non-surgical maxillary expansion on June 6, while Dr. J. Steven Alexander will discuss The Vivos Method's science on June 8. This participation underscores Vivos' commitment to advancing research in addressing dentofacial abnormalities and obstructive sleep apnea.